Skip to Content
Morningstar

Qiagen NV QGEN

Morningstar Rating
Unlock
Stock XNYS Rating as of
$42.13 −0.21 (0.50%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Qiagen Earnings: No Fair Value Estimate Change as Reset Period Continues About as Expected

Julie Utterback

Qiagen's first-quarter results mildly exceeded expectations, and our assumptions for 2024 remain within management's maintained guidance ranges for the full year. At first glance, we are maintaining our fair value estimate. Also, while our no-moat rating is intact, we recognize that Qiagen's operations have improved substantially in recent years, even when excluding pandemic-related demand, and we expect Qiagen to remain economically profitable throughout our five-year forecast period.

Read Full Report

Price vs Fair Value

View History
QGEN is trading at a 19% discount.
Price
$42.30
Fair Value
$67.00
Uncertainty
Medium
1-Star Price
$75.90
5-Star Price
$79.50
Economic Moat
Qtvt
Capital Allocation
Ypbgcjbk

Bulls Say, Bears Say

Bulls

Qiagen’s long-term growth prospects in the life science and diagnostic markets will not dissolve just because the pandemic turns into an endemic situation.

Bears

Competitive threats in Qiagen's chosen fields, particularly diagnostics, may always remain high given the risk of disruptive innovation from new and established organizations.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QGEN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$42.34
Day Range
$41.52–42.27
52-Week Range
$35.81–49.18
Bid/Ask
$42.09 / $42.12
Market Cap
$9.33 Bil
Volume/Avg
1.4 Mil / 1.0 Mil

Key Statistics

Price/Earnings (Normalized)
19.98
Price/Sales
4.81
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Qiagen NV offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Core
Total Number of Employees
6,000
Website
https://www.qiagen.com

Competitors

Valuation

View More
Metric
QGEN
DHR
ILMN
Price/Earnings (Normalized)
 19.9830.55143.37
Price/Book Value
 2.463.423.45
Price/Sales
 4.818.184.38
Price/Cash Flow
 14.6427.8334.70
Price/Earnings
QGEN
DHR
ILMN

Financial Strength

Metric
QGEN
DHR
ILMN
Quick Ratio
 1.461.341.14
Current Ratio
 1.991.851.66
Interest Coverage
 7.5715.85−14.26
Quick Ratio
QGEN
DHR
ILMN

Profitability

Metric
QGEN
DHR
ILMN
Return on Assets (Normalized)
 7.71%5.15%0.03%
Return on Equity (Normalized)
 13.14%8.40%0.06%
Return on Invested Capital (Normalized)
 8.51%6.02%0.21%
Return on Assets
QGEN
DHR
ILMN
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncWlwlslsdYqygy$220.2 Bil
DHR
Danaher CorpQvzcmkmwFvsyclw$182.8 Bil
IQV
IQVIA Holdings IncNrvcgrxYhcrwx$42.9 Bil
IDXX
IDEXX Laboratories IncGbkdkzjqyvSyzymm$42.0 Bil
A
Agilent Technologies IncHmvwxhsrNkyg$40.9 Bil
MTD
Mettler-Toledo International IncSrcpbbfdMwccdf$26.8 Bil
ICLR
Icon PLCLtbphddSwcwxsy$25.1 Bil
ILMN
Illumina IncXnssqjkBmrbbg$19.9 Bil
WAT
Waters CorpPkrgcrkgCgkd$18.7 Bil
LH
Laboratory Corp of America HoldingsVzvcypvpKbsxxqv$17.2 Bil

Sponsor Center